Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2024 | Infliximab versus vedolizumab in treating immune-mediated diarrhea and colitis

Yinghong Wang • 1 Jun 2024
ASCO 2024
General Antibodies Infliximab Vedolizumab

Yinghong Wang, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the preliminary findings of a randomized controlled trial (NCT04407247) comparing infliximab and vedolizumab in patients with immune-mediated diarrhea and colitis (IMDC). Both treatments showed similar high remission rates at two weeks and symptom improvement typically within three days. Most patients achieved steroid-free remission at one month, with a few experiencing symptom recurrence. Both drugs exhibited comparable safety profiles with mainly mild adverse events. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consulting or Advisory Role – BioNTech; Ilya Pharma; IOTA Pharmaceuticals; Janssen; Kanvas Biosciences; Mallinckrodt; Sorriso Pharmaceuticals
Patents, Royalties, Other Intellectual Property – Springer

More from Yinghong Wang

Outcome of radiation-related esophageal stricture from endoscopic dilation
1:38
Outcome of radiation-related esophageal stricture from endoscopic dilation
Yinghong Wang • 23 Jan 2025
Updates from the national Immune-Related Adverse Events (irAE) Consortium
1:41
Updates from the national Immune-Related Adverse Events (irAE) Consortium
Yinghong Wang • 23 Jan 2025
Recent progress in immunotherapy-induced GI toxicity research
1:38
Recent progress in immunotherapy-induced GI toxicity research
Yinghong Wang • 23 Jan 2025
Rationale and efficacy of fecal transplantation for ICI colitis
2:02
Rationale and efficacy of fecal transplantation for ICI colitis
Yinghong Wang • 1 Jun 2024

Related Videos

Pan-cancer TROP2 expression and survival in the MONSTAR-SCREEN-2 cohort
3:35
Pan-cancer TROP2 expression and survival in the MONSTAR-SCREEN-2 cohort
Kyosuke Seguchi • 23 Oct 2026
AI governance and validation in robotic cancer surgery
1:12
AI governance and validation in robotic cancer surgery
Marie Hanaoka • 1 Jul 2026
Does toxicity differ between patients treated with SABR for one versus five lesions?
0:39
Does toxicity differ between patients treated with SABR for one versus five lesions?
Robert Olson • 16 May 2026
5-year toxicity following SABR: insights from the SABR-5 trial
0:42
5-year toxicity following SABR: insights from the SABR-5 trial
Robert Olson • 16 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals